A Phase 2 Study of EMD 121974 (Cilengitide, NSC 707544) in Patients With Metastatic Melanoma
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2013
At a glance
- Drugs Cilengitide (Primary)
- Indications Malignant melanoma
- Focus Biomarker; Therapeutic Use
- 19 Dec 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 02 Jun 2012 Results published in Melanoma Research.
- 02 Jun 2010 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History